How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

A virus relies on the host's translation machinery to replicate itself and become infectious. Translation efficiency ...

Research about LENN -- a patent-pending, virus-mimicking platform technology that targets bladder cancer cells with mRNA ...

Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the ...

As a paediatrician in training, Jacqueline Miller was struck by how, every winter, she saw a steep rise in the numbers of patients with two conditions: respiratory syncytial virus (RSV) and rotavirus.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...